Clinical Report: OCT Biomarkers Predict Anti-VEGF Failure in DME
Overview
Revise to specify that 24% of patients had a good clinical response to anti-VEGF treatment.
Background
Diabetic macular edema (DME) is a leading cause of vision loss in diabetic patients, and anti-VEGF therapy is the first-line treatment. However, not all patients respond adequately, leading to the need for alternative therapies. Identifying biomarkers that predict treatment failure can optimize patient management and improve outcomes.
Data Highlights
| Parameter | Switch Required | No Switch |
|---|---|---|
| Mean Age | 69 years | 64.2 years |
| Initial BCVA | 0.3 | 0.5 |
| CRT | 492.3 µm | 351.4 µm |
| Female Patients | 43.5% | 18.2% |
Key Findings
- 76% of patients required a switch from anti-VEGF to DEX-i due to suboptimal response.
- Presence of two OCT biomarkers (SRF, HCW, VMI) increased odds of treatment failure by a factor of 49.
- All three biomarkers correlated with a near-certain failure of anti-VEGF therapy.
- Patients requiring a switch had worse baseline parameters, including higher CRT and lower BCVA.
- Women were more likely to require a switch in treatment compared to men.
Clinical Implications
Clinicians should consider OCT biomarkers when assessing patients with DME to identify those at risk of treatment failure. Early identification of nonresponders may justify switching to steroid therapy sooner, potentially improving patient outcomes.
Conclusion
The study underscores the importance of OCT biomarkers in predicting anti-VEGF treatment failure in DME, suggesting that timely intervention could enhance patient care.
References
- Retinal Physician, Non-CNV Predictors of Success of Anti-VEGF for AMD, 2020 -- Clarifying the role of biomarkers
- Ophthalmology Management, Applying HD-OCT to Diabetic Retinopathy, 2010 -- Recognition of distinct diabetic macular edema patterns
- Retinal Physician, RPS: From the Podium to the Practice, 2009 -- Insights on clinical care and research
- Diabetic Retinopathy Preferred Practice Pattern® - PubMed, 2023 -- Guidelines for DME management
- OCT Biomarkers Predict Anti-VEGF Failure in DME | Ophthalmology Management, 2025 -- Study findings on OCT biomarkers
- Ophthalmology Management — The current-care toolbox for DME
- Diabetic Retinopathy Preferred Practice Pattern® - PubMed
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial - PMC
- OCT Biomarkers Predict AntiVEGF Failure in DME | Ophthalmology Management
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
